Boston Scientific launches Precision Spectra Spinal Cord Stimulator System in the USA

201

According to the company, the Precision Spectra System is the world’s first and only spinal cord stimulation system with Illumina 3D software and 32 contacts, and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain. It has received US Food and Drug Administration (FDA) approval. Boston Scientific is expected to introduce the system at the annual meeting of the American Academy of Pain Medicine in Fort Lauderdale, USA.

“The Precision Spectra System represents a paradigm shift in spinal cord stimulation,” said Giancarlo Barolat, medical director of Barolat Neuroscience in Denver, USA. “The Illumina 3D Software is the first spinal cord stimulation system programming technology based on ports—twice that of any other spinal cord stimulation system—the Precision Spectra technology gives physicians more flexibility to customise therapy for patients.”

Until now, according to Boston Scientific, spinal cord systems have offered a maximum of 16 contacts and two lead ports, with each lead port allowing the placement of one lead. Additional lead ports give physicians more flexibility to cover their patients’ pain at the time of implant and more flexibility to adapt to changing pain patterns in the future. With more contacts, the Precision Spectra System also offers more coverage of the spinal cord for the management of chronic pain. 

“The Precision Spectra System is a major milestone in the advancement of spinal cord stimulation therapy,” said Maulik Nanavaty, president of the Neuromodulation business unit at Boston Scientific. 


Boston Scientific is expected to make continued investments in clinical studies to further understand the needs of chronic pain patients and has recently begun the following trials:

  • OPTIONS trial: An ongoing prospective, multicentre, single-arm study to further characterise the benefits of having a 32-contact option using the Precision Spectra System.
  • MAP trial: An ongoing cross-sectional, multicentre study to estimate the prevalence of multiple areas of pain in spinal cord stimulation-eligible patients with certain diseases.

In addition to the Precision Spectra System, Boston Scientific has recently new products in Europe and the USA, and has received expanded indications in Europe:  

  • Head-only magnetic resonance imaging conditional CE mark approval for the Precision Plus spinal cord stimulation system (not available for use or sale in the USA)
  • Peripheral nerve stimulation CE mark approval for the Precision Plus spinal cord stimulation system (in the USA, this is not available for use or sale)
  • Vercise Deep Brain Stimulator System CE mark approval for parkinson’s sisease (investigational device and not available for sale in the USA)
  • Infinion 16 Percutaneous spinal cord stimulation lead with US FDA and CE mark approval
(Visited 16 times, 1 visits today)